ONS vs. PRME, JATT, PLX, IKT, IZTC, ZIVO, CRTX, ALVR, CVM, and FNCH
Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Prime Medicine (PRME), JATT Acquisition (JATT), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), AlloVir (ALVR), CEL-SCI (CVM), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
Oncobiologics vs. Its Competitors
Oncobiologics (NASDAQ:ONS) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.
In the previous week, Prime Medicine had 6 more articles in the media than Oncobiologics. MarketBeat recorded 6 mentions for Prime Medicine and 0 mentions for Oncobiologics. Prime Medicine's average media sentiment score of 0.13 beat Oncobiologics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
Oncobiologics has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500.
Prime Medicine has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Prime Medicine's return on equity.
Oncobiologics has higher earnings, but lower revenue than Prime Medicine.
7.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 11.5% of Oncobiologics shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Prime Medicine has a consensus target price of $8.92, indicating a potential upside of 157.71%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Oncobiologics.
Summary
Prime Medicine beats Oncobiologics on 13 of the 15 factors compared between the two stocks.
Get Oncobiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Oncobiologics Competitors List
Related Companies and Tools
This page (NASDAQ:ONS) was last updated on 8/12/2025 by MarketBeat.com Staff